Celltrion Healthcare Co., Ltd.
091990
Rangering i aksjer
#2142
Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on... Celltrion Healthcare Co., Ltd. is a global pharmaceutical company focused on the development, manufacturing, and distribution of biosimilar and biological therapeutic agents for patients around the globe. Its product lineup includes Remsima, a monoclonal antibody biosimilar used to treat various inflammatory and autoimmune diseases such as rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis, Crohn's disease in both adults and children, psoriasis, and psoriatic arthritis. Another significant offering, Truxima, targets conditions like lymphoma, chronic lymphocytic leukemia, Wegener's granulomatosis, microscopic polyangiitis, and rheumatoid arthritis. Herzuma is prescribed for metastatic breast cancer, early-stage breast cancer, and metastatic gastric cancer. Additionally, Remsima SC provides a treatment option for rheumatoid arthritis. Founded in 1999, the enterprise was initially known as Nexol, Inc. before rebranding to Celltrion Healthcare Co., Ltd. in March 2009. The firm's corporate headquarters are situated in Incheon, South Korea.
Aksjekurs
$57.75
Sist synkronisert: 2024-01-11
Markedsverdi
$9.42B
Endring (1 dag)
-0.25%
Endring (1 år)
0.00%
Land
KR
Handel Celltrion Healthcare Co., Ltd. (091990)
Kategori
Healthcare
Antall utestående aksjer for Celltrion Healthcare Co., Ltd. (091990)
Antall utestående aksjer per October 2026: 0
Ifølge Celltrion Healthcare Co., Ltd. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 0. Ved slutten av October 2026 hadde selskapet 0 utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Celltrion Healthcare Co., Ltd. (091990) fra 2014 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2022 | 161.29M | -1.09% |
| 2021 | 163.07M | -0.86% |
| 2020 | 164.49M | 1.15% |
| 2019 | 162.62M | -0.10% |
| 2018 | 162.78M | 1.18% |
| 2017 | 160.89M | 37.16% |
| 2016 | 117.30M | 69.01% |
| 2015 | 69.40M | 20,550.84% |
| 2014 | 336.07K | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 253.90M | - |
US
|
|
| 396.00M | - |
US
|
|
| 478.91M | - |
AU
|
|
| 62.19M | - |
NL
|
|
| 0.00 | - |
BE
|
